Werkgroep Cardiologische centra Nederland

REDEFINE-3 (Recruiting)

randomised, double-blind, 2-armed, parallel-group, placebo-controlled trial primarily intended to assess the cardiovascular safety of CagriSema 2.4 mg/2.4 mg versus placebo, both administered subcutaneously (s.c.) once weekly in participants with obesity and established CVD
Medicine
CagriSema
Population
ASCVD
Phase
III
Starting year
2021

Director of Study

A.M. Otten (Cardioloog)
Apeldoorn, Gelre Ziekenhuizen